Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Ian Blumer; Jeremy H. Pettus; Tricia Santos Cavaiola

doi:10.1080/00325481.2018.1450058

Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Postgraduate Medicine ◽

10.1080/00325481.2018.1450058 ◽

2018 ◽

Vol 130 (4) ◽

pp. 375-380 ◽

Cited By ~ 4

Author(s):

Ian Blumer ◽

Jeremy H. Pettus ◽

Tricia Santos Cavaiola

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Fixed Ratio ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Clinical Diabetes ◽

10.2337/cd17-0065 ◽

2018 ◽

Vol 36 (2) ◽

pp. 138-147 ◽

Cited By ~ 4

Author(s):

Vanita R. Aroda ◽

Joseph R. Arulandu ◽

Anthony J. Cannon

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Two Agents ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Better Than

Download Full-text

Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2020.09.005 ◽

2020 ◽

Author(s):

Ronald M. Goldenberg ◽

Vineeta Ahooja ◽

Kristin K. Clemens ◽

Jeremy D. Gilbert ◽

Megha Poddar ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Sodium Dependent ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inhibitor Combination

Download Full-text

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 diabetes mellitus: A network meta‐analysis

Diabetes Obesity and Metabolism ◽

10.1111/dom.14202 ◽

2020 ◽

Vol 23 (1) ◽

pp. 136-146

Author(s):

Christopher K. Rayner ◽

Tongzhi Wu ◽

Vanita R. Aroda ◽

Craig Whittington ◽

Steve Kanters ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Meta Analysis ◽

Fixed Ratio ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Gastrointestinal Adverse Events

Download Full-text

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care ◽

10.2337/dc16-1957 ◽

2017 ◽

Vol 40 (4) ◽

pp. 614-624 ◽

Cited By ~ 52

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Annalisa Capuano ◽

Katherine Esposito ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1541790 ◽

2018 ◽

Vol 35 (5) ◽

pp. 793-804 ◽

Cited By ~ 3

Author(s):

Lawrence Blonde ◽

John E. Anderson ◽

Pavan Chava ◽

Jared A. Dendy

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Receptor Agonist ◽

Fixed Ratio ◽

Insulin Analog ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.14365 ◽

2021 ◽

Author(s):

Fernando Gomez‐Peralta ◽

Ebaa Al‐Ozairi ◽

Edward B. Jude ◽

Xiaoying Li ◽

Julio Rosenstock

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Receptor Agonist ◽

Fixed Ratio ◽

Premix Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s117200 ◽

2016 ◽

Vol Volume 9 ◽

pp. 19-29 ◽

Cited By ~ 11

Author(s):

Jay Lin ◽

Melissa Lingohr-Smith ◽

Tao Fan

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Real World ◽

Receptor Agonist ◽

Medication Persistence ◽

The Us ◽

Dose Combination ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study

Diabetes & Metabolism Journal ◽

10.4093/dmj.2021.0232 ◽

2021 ◽

Author(s):

Hwi Seung Kim ◽

Taekwan Yoon ◽

Chang Hee Jung ◽

Joong-Yeol Park ◽

Woo Je Lee

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Therapy ◽

Real World ◽

Receptor Agonist ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy of dapagliflozin in combination therapy with the glucagon-like peptide-1 analog in obese patients with type 2 diabetes

Diabetes Frontier Online ◽

10.15634/j0100_0201_008 ◽

2015 ◽

Vol 2 (e1) ◽

pp. 008-008

Author(s):

Momoko Isono ◽

Kazuya Fujihara ◽

Shoko Furukawa ◽

Ryo Kumagai ◽

Hiroaki Yagyu

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Obese Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text